The G7 Research Group presents the

2020 G7 Virtual Summit Final Compliance Report

17 March 2020 to 6 May 2021

Prepared by
Meagan Byrd
and the G7 Research Group

8 June 2021

www.g7.utoronto.ca

“...we have meanwhile set up a process and there are also independent institutions monitoring which objectives of our G7 meetings we actually achieve. When it comes to these goals we have a compliance rate of about 80%, according to the University of Toronto. Germany, with its 87%, comes off pretty well. That means that next year too, under the Japanese G7 presidency, we are going to check where we stand in comparison to what we have discussed with each other now. So a lot of what we have resolved to do here together is something that we are going to have to work very hard at over the next few months. But I think that it has become apparent that we, as the G7, want to assume responsibility far beyond the prosperity in our own countries. That’s why today’s outreach meetings, that is the meetings with our guests, were also of great importance.”

Chancellor Angela Merkel, Schloss Elmau, 8 June 2015

G7 summits are a moment for people to judge whether aspirational intent is met by concrete commitments. The G7 Research Group provides a report card on the implementation of G7 and G20 commitments. It is a good moment for the public to interact with leaders and say, you took a leadership position on these issues — a year later, or three years later, what have you accomplished?

Achim Steiner, Administrator, United Nations Development Programme,
in G7 Canada: The 2018 Charlevoix Summit
Contents

Introduction.........................................................................................................................3
Research Team ..................................................................................................................4
Summary.........................................................................................................................6
The Final Compliance Score .............................................................................................6
Compliance by Member ......................................................................................................6
Compliance by Commitment ..............................................................................................6
The Compliance Gap Between Members ..........................................................................6
Future Research and Reports .........................................................................................6
Table A: 2020 Priority Commitments Selected for Assessment*......................................8
Table B: 2020 G7 Virtual Summit Final Compliance Scores ..........................................9
Table C: 2020 G7 Virtual Summit Compliance Scores by Member ..................................10
Table D: 2020 G7 Virtual Summit Final Compliance Scores by Commitment .............11
1. Health: Public Health Measures .................................................................................12
2. Health: Addressing Risk .............................................................................................50
3. Health: Protecting Health and Safety ..........................................................................74
4. Health: Strengthening Health Systems ......................................................................114
5. Health: Data Sharing ..................................................................................................139
6. Health: Coordinated Research Efforts .........................................................................157
7. Health: Joint Research Projects ..................................................................................174
8. Health: Medical Equipment .......................................................................................187
9. Health: Online Platforms ............................................................................................211
10. Health: Supporting the World Health Organization ...................................................223
11. Health: Delaying the Spread of COVID-19 ...............................................................247
13. International Cooperation: Science, Research and Technology ..............................315
14. Global Economy: Restoring Confidence and Growth ..............................................331
15. Global Economy: Economic Growth .........................................................................347
17. Global Economy: Restoring Growth .........................................................................381
18. Trade: Supporting Trade and Investment ..................................................................406
19. Trade: Addressing International Supply Chains ......................................................428
20. Trade: Facilitating International Trade ..................................................................446
7. Health: Joint Research Projects

“We will support the launch of joint research projects funded by both public and private resources, and the sharing of facilities, towards rapid development, manufacture and distribution of treatments and a vaccine, adhering to the principles of efficacy, safety, and accessibility.”

_G7 Leaders’ Declaration_

<table>
<thead>
<tr>
<th>Assessment</th>
<th>No Compliance</th>
<th>Partial Compliance</th>
<th>Full Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>France</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>Italy</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>Japan</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>United States</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>European Union</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>Average</td>
<td></td>
<td></td>
<td>+1.00 (100%)</td>
</tr>
</tbody>
</table>

Background

On 16 March 2020, the G7 Leaders’ Declaration was issued in response to the COVID-19 pandemic and its effects on the global economy, specifically “support[ing] the launch of joint research projects funded by both public and private resources, and the sharing of facilities, towards rapid development, manufacture and distribution of treatments and a vaccine, adhering to the principles of efficacy, safety, and accessibility.”

The G7 has a long history of making broad commitments to support global health. Health as a feature was first mentioned at the 1980 Venice Summit in relation to the well-being of the public and the disposal of nuclear waste and production of nuclear energy. The 1983 Williamsburg Summit handed down the first commitment by the G7 to scientific health research.

The 1987 Venice Summit marked a major turning point. For the first time, separate health-related statements focused on global health crises were released by the G7. The first of these declarations “affirm[ed] that AIDS is one of the biggest potential health problems in the world” and laid out a pledge by G7 members to “intensify] and ma[k]e more effective … international cooperation and concerted campaigns to prevent AIDS from spreading further.” Also prominent are the first mentions of both the World Health Organization (WHO) and supporting the research and development of “a successful vaccine” by the scientific communities of the G7 members. The second release confirmed that a “drug abuse problem” that had “affect[ed] people all over the world, especially the young and their families” and noted the G7 had taken...
“multilateral” action to “fight against illegal production and distribution of [said] drugs.” Within the text of this statement by the G7, the first mentions of pediatric and family health emerges.

The 1991 London Summit included the first health-related mentions dedicated to specifically “improving health” of the poor in “developing countries” and G7 members. The 1993 Tokyo Summit produced the first commitment to increasing the accessibility “of the health care systems” and “medical services” of G7 members; also, elderly health was first mentioned, here. In the 1994 Naples Summit Communiqué, the first mention of the use of “private capital flows” to provide increased “resources” for global health. The 1996 Lyon Summit Chairman’s Statement generated the first pledge to tackle multiple “infectious diseases” and “epidemics,” simultaneously. The 1996 Lyon Summit was the first to acknowledge the negative impacts of environmental degradation on human health. The communiqué of the 1997 Denver Summit first pledged the G7 members to promoting therapies and therapeutics to fight infectious diseases.

The 2000 Okinawa Summit was the first G7 meeting to sponsor the use of “information and communications technologies” to increase the efficiency and efficacy of health systems. During the 2003 Evian Summit, the G7 members pledged to confront the – at the time – pressing SARS epidemic sweeping across the globe. The 2004 Sea Island Summit’s Global HIV Vaccine Enterprise was a key initiative in the history of the G7 and global health. For the first time, the G7 laid out a “strategic plan” for dealing with an infectious disease; concomitantly, the Global HIV Vaccine Enterprise was also the first mention of sharing of facilities, phrased as “coordinated global HIV Vaccine Development Centers,” by the G7.

The 2010 Muskoka Summit marks another major accessibility milestone, the prioritization of women’s health in the Muskoka Initiative on Maternal, Newborn and Under-Five Child Health. The 2014 Brussels Summit was the first to address the “Ebola outbreak in West Africa” in light of its rapid spread in that region. The 2015 Schloss Elmau Summit explicitly prioritized the fight against Ebola and neglected tropical diseases, along with being the first declaration which seeks to “prevent future outbreaks from becoming epidemics” or pandemics instead of merely attempting to fight or contain infectious diseases.

On 31 December 2019, the WHO first alerted the world of the new SARS-CoV-2 virus, following a report of a new viral pneumonia emerging in the People’s Republic of China. The virus quickly spread across the world and forcing the world economy to slow as the countries experienced mass lockdowns. In response, on 3 February 2020, G7 health ministers held a conference call to discuss COVID-19. On 16 March, under the U.S. presidency, G7 leaders met virtually and made commitments on vaccines as well as in the areas of medical equipment, public access to virus-related information, weekly governmental coordination, epidemiological data sharing, improving virus containment, and a strong international approach. At the time, they expected to meet again in three months at their regularly scheduled summit on 10-12 June 2020, which was later postponed indefinitely.

**Commitment Features**

The G7 commitment is to “support the launch of joint research projects funded by both public and private resources, and the sharing of facilities, towards rapid development, manufacture and distribution of treatments and a vaccine, adhering to the principles of efficacy, safety, and accessibility.” There are two components to this commitment: 1) support[ing] the launch of joint research projects funded by both public and private resources, including sharing of facilities; and 2) by sharing of facilities.

Thus, it is understood that funding for joint research projects needs to be derived from both the G7 member and a private organization’s resource pools to be counted for full compliance. It is also clear that a G7 member must share facilities with another member to count for full compliance.

Actions need to be related to the “launch of joint research projects … and the sharing of facilities,” and, the “development, manufacture, and distribution of treatments and a vaccine,” wherein support refers to “the action, or act of providing aid, assistance, or backing up an initiative, or entity.”

“Launch,” implies that joint research projects and the sharing of facilities are “put into operation or set in motion.” “Joint” is “common to two or more: such as involving the united activity of two or more.”

“Research” is defined as a “to search or investigate exhaustively.” “Project” is seen as “a planned undertaking: such as a large usually government-supported” task. Therefore, a “joint research project” is defined as a united activity common to two or more entities, wherein a planned search or exhaustive investigation is undertaken by a government or government-supported entity.

“Resources” are “a source of supply or support: an available means” to a specified end. “Public” denotes “of, relating to, or being in the service of the community or nation.” “Private” designates “belonging to or concerning an individual person, company, or interest.”

“Public resources” are a source of supply, source of support, and/or an available means being used in the service of the community or nation to support the launch of joint research projects or the sharing of facilities by two or more governments or government-supported

---

entities. “Private resources” are a source of supply, source of support, and/or an available means belonging to or concerning an individual person, company, or interest being used to support the launch of joint research projects or the sharing of facilities by two or more governments or government-supported entities.

“Sharing” is to “partake of, use, experience, occupy, or enjoy with others” or “to grant or give share in” something.1513 “Facilities” are places or things “built, installed, or established to serve a particular purpose.”1514 In the context of this commitment, “sharing of facilities” can be noted as the use or occupation of built, installed, or established places or things by two or more governments or government-supported entities in pursuit of the launch of joint research projects. Concurrently, “sharing of facilities” is the granting of use of purpose built, installed, or established places or things by two or more governments or government-supported entities in pursuit of the launch of joint research projects.

For full compliance, G7 members must take action on both components of this commitment. G7 members must support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities. Joint research projects can include, but are not limited to, the WHO’s COVAX, COVID-19 Solidarity Response Fund, and Access to COVID-19 Tools (ACT) Accelerator, and the United Nations’ COVID-19 Supply Chain Task Force. To receive a score of partial compliance, or 0, G7 members must have taken action towards supporting the launch of joint research projects funded by both public and private resources, or participating in the sharing of facilities, but not both. A score of -1, or no compliance, will be assigned if the G7 member exemplifies no demonstrable compliance towards supporting the launch of joint research projects funded by both public and private resources, or participating in the sharing of facilities.

**Scoring Guidelines**

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>-1</td>
<td>G7 member has NOT taken any action towards supporting the launch of joint research projects funded by both public and private resources OR participated in the sharing of facilities.</td>
</tr>
<tr>
<td>0</td>
<td>G7 member has taken actions toward EITHER supporting the launch of joint research projects funded by both public and private resources OR participating in the sharing of facilities.</td>
</tr>
<tr>
<td>+1</td>
<td>G7 member has taken actions toward supporting the launch of joint research projects funded by both public and private resources AND participating in the sharing of facilities.</td>
</tr>
</tbody>
</table>

**Canada: +1**

Canada has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 2 April 2020, Canada increased its investment in COVID-19 research to CAD54.2 million, supporting 99 private and public research teams across the country.1515

On 17 June 2020, the Canadian government launched the Global Partnership on Artificial Intelligence (GPAI), an initiative co-created with France and housed in a shared facility in Paris.1516 During the pandemic, the GPAI will focus all research on the use of artificial intelligence for battling COVID-19.1517

On 25 June 2020, Minister of Health Patty Hajdu announced an investment of CAD109 million in COVID-19 research through the Canadian Institutes of Health Research and the International Development Research Centre, supporting 139 research teams in both domestic and international clinical trials.\(^{1518}\)

On 14 December 2020, Canada announced a total contribution of CAD485 million to procure treatments for developing countries in response to urgent priorities identified by the COVID-19 Tools (ACT) Accelerator, including CAD255 million to support the effective deployment of medical solutions against COVID-19 in developing and vulnerable countries.\(^{1519}\)

On 18 December 2020, the World Health Organization announced Canada’s pledge of CAD75 million to the COVID-19 Vaccine Global Access (COVAX) Advance Market Commitment to assist the delivery of COVID-19 vaccines in low-income countries.\(^{1520}\) A part of this pledge is CAD5 million that will be invested toward the development of an equitable mechanism for vaccine reallocation through the COVAX facility by donation or exchange.\(^{1521}\)

On 19 February 2021, Canada increased its investment in the COVAX facility by pledging an additional CAD75 million to the Access to COVID-19 Tools Accelerator with funds allocated for vaccine delivery in low- and middle-income countries.\(^{1522}\)

Canada has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, Canada receives a score of +1.

**Analyst: Sian Persad**

**France: +1**

France has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 2 April 2020, the Minister of Higher Education, Research, and Innovation released a fund of EUR50 million to the Ministry of Solidarity and Health to be allocated to applied COVID-19 research efforts.\(^{1523}\) The

---


On 8 February 2021, the WHO announced that France had contributed EUR10 million to support the ACT and the implementation of a COVID-19 preparedness and response plan.\footnote{France and WHO: a strategic partnership for global health security, World Health Organization (Lyon) 8 February 2021. Access Date: 1 April 2021. https://www.who.int/news/item/08-02-2021-france-and-who-a-strategic-partnership-for-global-health-security.}

On 18 February 2021, French President Emmanuel Macron proposed that the G7 sends 5 per cent of its COVID-19 vaccines to less developed countries and expressed support for funding vaccine manufacturing in African countries.\footnote{Macron proposes vaccine sharing plan as UK prepares to host G7, The Guardian (London) 18 February 2021. Access Date: 1 April 2021. https://www.theguardian.com/world/2021/feb/18/macron-proposes-vaccine-plan-as-uk-prepares-to-host-g7.}

France has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.
Thus, France receives a score of +1.

Analyst: Shauna McLean

Germany: +1

Germany has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 4 May 2020, Germany attended a European Union-organized COVID-19 summit and contributed approximately EUR500 million for COVID-19 research.\textsuperscript{1535}

As of 10 July 2020, the Deutsche Forschungsgemeinschaft was funding multiple international COVID-19 research projects, including partnerships with the Peruvian government and with the Government of India.\textsuperscript{1536} The Deutsche Forschungsgemeinschaft is 69 per cent funded by the German government through the Ministry of Education and Research.\textsuperscript{1537}

As of 27 October 2020, 97 COVID-19 studies were registered in Germany facilities, almost half of which were international studies sharing German resources.\textsuperscript{1538}

On 19 February 2021, the German government announced that it will be providing the Access to COVID-19 Tools Accelerator with EUR1.5 billion in 2021, in addition to previous contributions totalling EUR600 million.\textsuperscript{1539} This funding will go primarily to the shared COVID-19 Vaccine Global Access (COVAX) facility to provide more vaccines and support COVID-19 research.\textsuperscript{1540}

On 19 February 2021, Germany announced an additional EUR900 million in funding for COVAX in partnership with other European Union member states and Team Europe.\textsuperscript{1541}

Germany has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, Germany receives a score of +1.

Analyst: Shauna McLean

Italy: +1

Italy has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 4 June 2020, Italy pledged USD79 million to the COVID-19 Vaccines Global Access (COVAX) Advanced Market Commitment (AMC) initiative at the Global Vaccine Summit; the COVAX AMC initiative finances the COVAX facility.\(^\text{1542}\) This contribution supports 92 low- and middle-income countries’ access to COVID-19 vaccines.\(^\text{1543}\)

On 10 September 2020, Italy, along with heads of state and ministers from 30 other states, released a joint statement on the first meeting of the Access to COVID-19 Tools (ACT) Accelerator Facilitation Council.\(^\text{1544}\) The statement committed to providing sustained political leadership to galvanize support for the ACT-Accelerator, advocating in support of the ACT-Accelerator Investment Case, and honouring and realizing a shared commitment to leave no one behind in this crisis.\(^\text{1545}\)

On 2 October 2020, Italian private resources under the ownership of Vismederi, a Siena-based clinical sampling testing laboratory partnered with the publically funded University of Siena, joined the Coalition for Epidemic Preparedness Innovation’s (CEPI) new Centralised Lab Network to reliably assess and compare the immunological responses generated by COVID-19 vaccine candidates; partner laboratories include the United Kingdom Department of Health’s Public Health England, Nexelis of Canada, Viroclinics-DDL of the Netherlands, the International Centre for Diarrhoeal Disease Research of Bangladesh, and the Indian Ministry of Science and Technology’s Translational Health Science and Technology Institute.\(^\text{1546}\)

On 6 October 2020, Italy pledged an additional EUR20 million to the COVAX AMC initiative.\(^\text{1547}\) This contribution raises Italy’s total contribution to the COVAX AMC initiative to USD102 million.\(^\text{1548}\)

On 28 October 2020, Italy formally joined CEPI with an initial donation of EUR5 million out of a committed EUR10 million pledge.\(^\text{1549}\)

---


On 23 March 2021, Italian Vice Foreign Minister Marina Sereni reiterated Italian support for the COVID-19 ACT Accelerator and COVAX AMC by calling for increased financial contributions to both programs. Additionally, Vice Foreign Minister Sereni committed Italian G20 Presidency at the Global Health Summit to discussing both COVAX and the ACT Accelerator initiatives.\textsuperscript{1550}

Italy has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, Italy receives a score of +1.

\textit{Analyst: Ben Holt}

\textbf{Japan: +1}

Japan has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 8 October 2020, the Japanese Government announced that it was pledging USD130 million to the COVID-19 Vaccine Global Access (COVAX) Advance Market Commitment; the COVAX AMC initiative finances the COVAX facility.\textsuperscript{1551}

On 9 February 2021, at the Access to COVID-19 Tools Accelerator 4th Facilitation Council, the Minister for Foreign Affairs of Japan, Mr. Motegi Toshimitsu, announced that Japan would increase its contribution to the COVAX AMC to a total of USD200 million.\textsuperscript{1552} COVAX aims to accelerate the development and manufacturing of COVID-19 vaccines, while also guaranteeing fair and equitable access of the vaccine for every country in the world.\textsuperscript{1553}

On 9 March 2021, the Japanese Government extended an Emergency Grant Aid of USD41 million to 25 Southeast and Southwest Asian countries suffering from the impacts of COVID-19. The donation provided medical equipment and cold-storage facilities through the United Nations Children’s Fund (UNICEF) and was aimed to compliment the efforts of the COVAX Facility.\textsuperscript{1554}

Japan has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, Japan receives a score of +1.

\textit{Analyst: Maryam Rehman}

**United Kingdom: +1**

The United Kingdom has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 23 March 2020, the United Kingdom invested GBP20 million to launch genome research in tandem with the National Health Service and various academic institutions to map the spread of the COVID-19 pandemic.\(^{1555}\) This funding will supplement six research projects across the United Kingdom, including vaccination trials.\(^{1556}\)

On 23 March 2020, the United Kingdom launched a technology challenge promising funding of up to GBP500,000 for companies developing methods to optimize care, volunteerism and support for people during the pandemic.\(^{1557}\)

On 29 May 2020, the United Kingdom announced an investment of GBP5 million in community research projects that address mental health issues during the COVID-19 pandemic, funding grassroots organizations working to create access to resources and guidelines for surviving the pandemic.\(^{1558}\)

On 25 September 2020, Prime Minister Boris Johnson announced during a speech to the United Nations General Assembly that the United Kingdom would become the World Health Organization’s largest state donor with an increase in funding by 30 per cent.\(^{1559}\) The prime minister also pledged GBP500 million to the COVID-19 Vaccine Global Access (COVAX) Advance Market Commitment.\(^{1560}\)

On 2 October 2020, the United Kingdom Department of Health’s Public Health England joined the Coalition for Epidemic Preparedness Innovation’s new Centralised Lab Network to reliably assess and compare the immunological responses generated by COVID-19 vaccine candidates; partner laboratories include Vismederi of Italy, Nexelis of Canada, Viroclinics-DDL of the Netherlands, the International Centre for Diarrhoeal Disease Research of Bangladesh, and the Indian Ministry of Science and Technology’s Translational Health Science and Technology Institute.\(^{1561}\)

---


On 7 February 2021, the United Kingdom Vaccine Taskforce and National Institute for Health Research French partnered with French vaccine developer Valneva to begin manufacturing its own vaccine. Valneva had reached a deal with the United Kingdom government for 60 million doses by the end of 2021.\textsuperscript{1562} The United Kingdom has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, the United Kingdom receives a score of +1.

\textbf{United States: +1}

The United States has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 21 May 2020, the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARD\textsuperscript{a}) announced a partnership with AstraZeneca to support and expedite the development of a COVID-19 vaccine.\textsuperscript{1563} Under the terms of the partnership, BARD\textsuperscript{a} agreed to provide AstraZeneca with up to USD1.2 billion in funding.\textsuperscript{1564}

On 21 January 2021, President Joseph Biden issued a National Security Memorandum in part expressing the United States’ plans to assist the Access to COVID-19 Tools Accelerator and join the COVID-19 Vaccine Global Access (COVAX) facility, which facilitates the distribution of COVID-19 vaccines worldwide.\textsuperscript{1565}

On 19 February 2021, the United States pledged an initial USD2 billion in funding at a virtual G7 leaders meeting for the COVAX Advance Market Commitment (AMC), which finances the COVAX Facility.\textsuperscript{1566} The United States also announced an additional contribution of USD2 billion to COVAX AMC for 2021 and

---


2022. The first USD500 million of the additional contribution will be released when existing donor pledges are satisfied, and initial doses of the COVID-19 vaccine are provided to AMC countries.

The United States has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, the United States receives a score of +1.

**European Union: +1**

The European Union has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

On 20 April 2020, the European Union launched a European COVID-19 Data Platform to facilitate the collection and sharing of research data on COVID-19. As part of the ERAvsCorona Action Plan, the platform was a milestone in the European Union’s efforts to support researchers in Europe and worldwide in the fight against COVID-19. The platform boosts research discovery, allowing for an effective response to COVID-19, and constitutes a sharing of European Union facilities in an online space.

On 18 June 2020, the European Innovation Council announced that it would be funding eight French government-sponsored health projects for up to EUR57.4 million.

On 11 August 2020, the European Union distributed EUR128 million in funding to 23 new research projects working on COVID-19 treatments and responses. These efforts support the development of diagnostics, treatments, and vaccines for COVID-19.

On 12 November 2020, the European Union increased its total contribution to the COVID-19 Vaccine Global Access (COVAX) facility to EUR500 million by providing an additional EUR100 million. COVAX is a pillar of the Access to COVID-19 Tools Accelerator.

---


On 15 December 2020, the European Investment Bank agreed to provide EUR400 million in financing for COVAX to support the initiative’s goal of ensuring fair and equitable access to the COVID-19 vaccine worldwide.\textsuperscript{1577} The European Commission also contributed a EUR100 million grant to COVAX Advance Market Commitment.\textsuperscript{1578}

On 19 February 2021, the European Union announced that it had doubled its contribution to the COVAX Facility from EUR500 million to EUR1 billion to support the initiative in its efforts to distribute COVID-19 vaccines around the world.\textsuperscript{1579}

On 7 April 2021, the European Commission announced that it was mobilizing EUR123 million from Horizon Europe, the European Union’s new research and innovation programme, to conduct research on COVID-19 variants.\textsuperscript{1580} The European Commission also launched new calls for solutions and projects that support the development of research networks and the reinforcement of research infrastructure related to COVID-19 and/or SARS-CoV-2 and its variants.\textsuperscript{1581} The projects will establish new and/or build on existing research cohorts to further knowledge on SARS-CoV-2 variants. They will also further develop vaccines and support research infrastructures that will facilitate data sharing, help combat variants, and increase preparedness for future pandemics.\textsuperscript{1582}

The European Union has fully complied with its commitment to support the launch of joint research projects funded by both public and private resources and participate in the sharing of facilities.

Thus, the European Union receives a score of +1.

\textit{Analyst: Maryam Rehman}

\begin{itemize}
\end{itemize}